Drug Discovery Program
Welcome to Lübeck Biosciences Discovery Program, where our mission is to develop innovative treatments for some of the most pressing health issues of our time. As an expert team of biomedical scientists, we are harnessing the power of artificial intelligence (AI) to combat aging, neurodegeneration, autoimmune diseases, and cancer. Our goal is to transform healthcare and improve the quality of life for millions of people worldwide.
Aging: A Growing Global Health Challenge
Aging is an inevitable and complex biological process that affects every individual, leading to a progressive decline in physical and cognitive functions. By 2050, the global population aged 60 and over is projected to reach 2.1 billion, accounting for 21.5% of the world’s population (United Nations, 2021). As life expectancy continues to rise, the prevalence of age–related diseases, such as cardiovascular diseases, neurodegenerative disorders, and cancer, is also increasing. For instance,Alzheimer’s disease, the most common form of dementia, affects approximately 50 million people worldwide, and this number is expected to triple by 2050 (World Health Organization, 2021). By using AI to understand the molecular mechanisms behind aging and developing targeted interventions, Lübeck Biosciences aims to enhance the quality of life for the aging population and reduce the burden of age–related disease
Neurodegeneration: The Growing Impact on Patients
Neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis (ALS), are characterized by the progressive loss of structure and function of neurons. Currently, Alzheimer’s disease alone affects an estimated 50 million people worldwide, with a new case being diagnosed every three seconds (World Health Organization, 2021). Parkinson’s disease, the second most common neurodegenerative disorder, afflicts about 10 million people globally (Parkinson’s Foundation, 2021). Lübeck Biosciences employs AI-driven research to develop effective treatments and halt the progression of these debilitating conditions
Autoimmune Diseases: The Prevalence and Impact on Patients
Autoimmune diseases, encompassing more than 80 distinct disorders, affect approximately 4% of the global population (Cooper et al., 2009). In the United States alone, 23.5 million people suffer from these conditions, with women disproportionately affected (National Institutes of Health, 2021). Some of the most common autoimmune diseases include multiple sclerosis, which impacts more than 2.3 million people worldwide (Multiple Sclerosis International Federation, 2020), and rheumatoid arthritis, affecting about 1% of the global population (World Health Organization, 2021). Lübeck Biosciences utilizes AI to identify novel targets and develop therapies that modulate the immune system, providing relief to those suffering from these debilitating conditions.
Cancer: A Persistent Global Health Threat
Cancer remains a significant global health challenge, with an estimated 19.3 million new cases and 10 million cancer-related deaths reported in 2020 (World Health Organization, 2021). It is the second leading cause of death worldwide, accounting for one in every six deaths. The most common types of cancer include lung, breast, colorectal, and prostate cancer. Lübeck Biosciences leverages AI to uncover new targets for cancer therapy and develop drugs that can selectively kill cancer cells while minimizing harm to healthy tissue. By employing AI-based precision medicine, we aim to offer personalized cancer treatments, increasing the chances of successful outcomes.
Harnessing the Power of AI for Drug Discovery
Lübeck Biosciences is at the forefront of integrating AI into drug discovery, transforming the way we approach the most challenging health issues of our time
01. Expedite drug discovery:
AI-driven screening techniques can rapidly identify potential drug candidates, significantly reducing the time and cost associated with traditional drug development processes.
02. Improve drug efficacy and safety:
AI-based predictive models can help us anticipate potential side effects, drug interactions, and off-target effects, ensuring the development of safer and more effective therapeutics.
03. Personalize medicine:
AI-driven analysis of individual genetic information and disease profiles can lead to the development of targeted therapies tailored to specific patient needs.
Uncover novel therapeutic targets: AI algorithms can process vast amounts of biomedical data to identify previously unknown biological-pathways and targets, opening new avenues for innovative treatments.